What is BAXFENDY™ (baxdrostat) and what is it approved for?

The FDA has approved BAXFENDY™ for the treatment of hypertension in adults. It is indicated as an add-on therapy for patients whose blood pressure is not adequately controlled with existing antihypertensive medications.

How does BAXFENDY work?

BAXFENDY is an aldosterone synthase inhibitor (ASI) that directly and selectively blocks aldosterone production in the adrenal gland, addressing fluid retention, arterial stiffening, and elevated systemic blood pressure at its source.

How prevalent is treatment-resistant hypertension in the U.S.?

Approximately 23 million U.S. adults have persistently elevated blood pressure despite taking two or more standard antihypertensive drugs, representing the primary target population for BAXFENDY.

What clinical evidence supports BAXFENDY’s FDA approval?

The pivotal BaxHTN Phase III trial enrolled 796 participants on multiple blood pressure therapies. The 2mg daily dose reduced seated systolic blood pressure by an absolute mean of 15.7 mmHg (placebo-adjusted reduction of 9.8 mmHg, p<0.001). The 1mg dose produced a 14.5 mmHg absolute reduction (placebo-adjusted 8.7 mmHg, p<0.001).

FDA approves AstraZeneca’s BAXFENDY™ as first-in-class hypertension treatment

Q: Why is BAXFENDY significant for hypertension treatment?

This is the first FDA-approved ASI for commercial use, introducing a new mechanism of action for treatment-resistant and uncontrolled hypertension, a segment with minimal specialized pharmacological innovation over the past 20 years.

Written by Heidi Cuthbert Published May. 18 2026Last Updated May. 18 2026

AstraZeneca (NASDAQ:AZN) announced that the U.S. Food and Drug Administration (FDA) has approved BAXFENDY™ (baxdrostat) for the treatment of hypertension in adults.

The oral therapeutic is indicated as an add-on therapy in combination with other antihypertensive medications to lower blood pressure in individuals whose conditions are not adequately managed on their current drug regimens.

The decision introduces a completely new mechanism of action to the cardiovascular care sector, marking the first time an aldosterone synthase inhibitor (ASI) has achieved regulatory approval for commercial use.

Hypertension remains a widespread global public health challenge, impacting approximately 1.4 billion people worldwide and acting as a primary, modifiable driver of serious cardiovascular disease, stroke, kidney damage, and premature death.

Within the United States alone, an estimated 23 million patients struggle with persistently elevated blood pressure despite actively taking two or more standard-of-care antihypertensive drugs.

This specific patient population faces heightened long-term risks, as the therapeutic space for treatment-resistant and uncontrolled hypertension has experienced minimal specialized pharmacological innovation over the past two decades.

BAXFENDY bypasses traditional pathway-blocking strategies by directly and selectively inhibiting the production of aldosterone.

The hormone is naturally synthesized by the adrenal gland, but hyperproduction or elevated levels can lead to pathological fluid retention, arterial stiffening, and subsequent systemic blood pressure escalation.

By stopping aldosterone at its enzymatic source, BAXFENDY addresses a root physiological cause of uncontrolled hypertension, introducing a distinct line of defense for clinical practitioners managing complex patient profiles.

The FDA's decision was supported by robust clinical data derived from the pivotal BaxHTN Phase III trial, which evaluated the efficacy and safety of the compound over a 12-week placebo-controlled treatment window.

The study enrolled 796 participants taking multiple foundational blood pressure therapies, including a diuretic.

Patients randomized to receive a once-daily 2mg dose of BAXFENDY achieved an absolute mean reduction of 15.7 mmHg in seated systolic blood pressure (SBP), yielding a statistically significant, placebo-adjusted reduction of 9.8 mmHg (p<0.001).

Individuals on the 1mg dose also demonstrated meaningful progress, posting an absolute baseline reduction of 14.5 mmHg and a placebo-adjusted drop of 8.7 mmHg (p<0.001).

AstraZeneca plans to integrate BAXFENDY into its core global biopharmaceuticals infrastructure, preparing for an immediate domestic commercial launch while continuing advanced clinical programs exploring the drug's utility in treating chronic kidney disease and heart failure.